top of page
brigatinib_banner.jpg

Home / Information / Brigatinib

Brigatinib

Brigatinib is a 2nd generation TKI developed by Takeda. The recommended dose is 180mg taken daily.

Documents

Name

Summary of Contents

Action

NICE Approves Brigatinib

This document explains Brigatinib for treating ALK+ NSCLC after crizotinib

Download

Image
Image

ALK Positive Lung Cancer (UK) is committed to producing reliable, accurate and up-to-date content reflecting the best available research evidence and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest.

​

ALK Positive Lung Cancer (UK) is a registered charity in England and Wales ((1181171) and Scotland (SC053692).  The registered office is at 1 Ethley Drive, Raglan, Monmouthshire, NP15 2FD.

The content of this website is for information only and should not be used for the diagnosis or treatment of medical conditions.  We are unable to offer specific medical advice and, if you are worried about any symptoms, you should consult your doctor.​​

View our privacy policy HERE        View our consent policy HERE

No part of this publication may be reproduced or tansmitted in any form or by any means, electronically, mechanically or manually without permission in writing of ALK Positive Lung Cancer (UK).

bottom of page